Cart
sales@molnova.com
Heveaflavone
CAS No. 23132-13-0
Heveaflavone( —— )
Catalog No. M29164 CAS No. 23132-13-0
Heveaflavone has anti-proliferation effects, it shows moderate Topoisomerase I inhibitory activity. It also possesses a good antioxidant activity via its DPPH free radical scavenging.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHeveaflavone
-
NoteResearch use only, not for human use.
-
Brief DescriptionHeveaflavone has anti-proliferation effects, it shows moderate Topoisomerase I inhibitory activity. It also possesses a good antioxidant activity via its DPPH free radical scavenging.
-
DescriptionHeveaflavone has anti-proliferation effects, it shows moderate Topoisomerase I inhibitory activity. It also possesses a good antioxidant activity via its DPPH free radical scavenging.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
RecptorTopoisomerase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number23132-13-0
-
Formula Weight580.545
-
Molecular FormulaC33H24O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1ccc(cc1)-c1cc(=O)c2c(O)cc(OC)c(-c3cc(ccc3O)-c3cc(=O)c4c(O)cc(OC)cc4o3)c2o1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Etoposide
Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
-
Pirarubicin
Pirarubicin is an anthracycline antibiotic, and also a DNA/RNA synthesis inhibitor by intercalating into Dna and interacts with topoisomerase II, used as an antineoplastic agent.
-
Proscillaridin A
Proscillaridin A is a natural product.It is a potent poison of topoisomerase I/II activity with IC50 values of 30 nM and 100 nM, respectively.
